EP0003089B1 - Séchoir pour feuilles imprimées par sérigraphie - Google Patents

Séchoir pour feuilles imprimées par sérigraphie Download PDF

Info

Publication number
EP0003089B1
EP0003089B1 EP19780400265 EP78400265A EP0003089B1 EP 0003089 B1 EP0003089 B1 EP 0003089B1 EP 19780400265 EP19780400265 EP 19780400265 EP 78400265 A EP78400265 A EP 78400265A EP 0003089 B1 EP0003089 B1 EP 0003089B1
Authority
EP
European Patent Office
Prior art keywords
hurdle
conveyor
sheet
clips
bent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP19780400265
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0003089A1 (fr
Inventor
Bernard David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silium Francaise A Responsabilite Ltee Ste
Original Assignee
Silium Francaise A Responsabilite Ltee Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0003089(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silium Francaise A Responsabilite Ltee Ste filed Critical Silium Francaise A Responsabilite Ltee Ste
Publication of EP0003089A1 publication Critical patent/EP0003089A1/fr
Application granted granted Critical
Publication of EP0003089B1 publication Critical patent/EP0003089B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Definitions

  • the present invention relates to a dryer for sheets printed by screen printing.
  • the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
  • a first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. Leaving the tunnel, the leaves are dry and are removed from the machine.
  • a second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed.
  • This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place.
  • Another disadvantage of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
  • GB-A-793 216 describes a dryer without racks, in which the sheets are dried by blowing hot air flat on a table located in the upper part of the dryer.
  • the absence of racks is very annoying since the leaves can come to press against each other during their movement.
  • the insertion of the sheets into the tongs and their unloading are done in two separate consecutive operations.
  • This conveyor 1 is carried by a frame 5 in the middle of which is arranged a device 6 for blowing air of a type known per se.
  • Each series of pliers 9 is constituted, in the example shown, by a row of bent blades 12 (FIG. 3), rotatably mounted around axes or pins 13 parallel to the adjoining side of the rack 7, secured to the endless conveyor 1
  • the blades 12, preferably metallic, are bent in the example shown by forming an angle of approximately 120 degrees, the axes 13 being placed inside this angle, and supporting the blades 12 by means of ears 14 integral with the blades and in which the pins 13 are threaded.
  • the mooring device constituted by the clamps according to the invention, it is possible to ventilate with increased force, the sheets dry more quickly.
  • a lower number of racks is necessary to dry a determined quantity of sheets in a given time interval, which makes it possible to reduce the size of the machine by reducing the number of racks which it can contain.
  • the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the heads 17 and on which the clamps would come. '' open when reaching horizontal.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
EP19780400265 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie Expired EP0003089B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7800305 1978-01-06
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Publications (2)

Publication Number Publication Date
EP0003089A1 EP0003089A1 (fr) 1979-07-25
EP0003089B1 true EP0003089B1 (fr) 1981-08-12

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19780400265 Expired EP0003089B1 (fr) 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie

Country Status (3)

Country Link
EP (1) EP0003089B1 (enExample)
DE (1) DE2860970D1 (enExample)
FR (1) FR2413974A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Families Citing this family (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
IL126383A0 (en) 1996-04-01 1999-05-09 Genentech Inc Apo-2li and apo-3 apoptosis polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6136958A (en) 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
WO2001040466A2 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
WO1998056808A1 (en) * 1997-06-13 1998-12-17 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
CA2303225C (en) 1997-09-18 2015-03-31 Genentech, Inc. Dna30942 polypeptide, a tnfr homolog
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
IL135607A0 (en) 1997-10-29 2001-05-20 Genentech Inc Wnt-1 inducible genes
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69840105D1 (de) 1997-11-21 2008-11-20 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
JP2002505850A (ja) 1997-12-03 2002-02-26 ジェネンテック・インコーポレーテッド ポリペプチド及び同じものをコードしている核酸
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
EP1484338B1 (en) 1998-12-22 2007-02-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP2112167A3 (en) 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
IL148114A0 (en) 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1897944B1 (en) 1999-12-23 2011-08-10 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
PT1246917E (pt) 2000-01-13 2009-06-02 Genentech Inc Polipéptidos stra6 humanos
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
ES2371748T3 (es) 2001-05-30 2012-01-09 Genentech, Inc. Anticuerpos anti-ngf para el tratamiento de diversos trastornos.
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
SI1427830T1 (sl) 2001-08-29 2012-08-31 Genentech Inc Bv8 nukleinske kisline in polipeptidi z mitogensko aktivnostjo
ES2390531T3 (es) 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US20070048301A1 (en) 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EA011479B1 (ru) 2002-12-24 2009-04-28 Ринат Ньюросайенс Корп. Антитело связывающееся с ngf, и способы его применения
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
AU2003237792A1 (en) 2003-04-01 2004-11-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2251355A1 (en) 2003-05-30 2010-11-17 Genentech, Inc. Treatment with anti-VEGF antibodies
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
ATE465275T1 (de) 2003-06-13 2010-05-15 Univ Pittsburgh Überwachung von immunologischen, hämatologischen und entzündlichen erkrankungen
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
ZA200610158B (en) 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
NZ556095A (en) 2005-01-21 2010-01-29 Genentech Inc Fixed dosing of her antibodies
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
EP1869184B1 (en) 2005-04-11 2011-09-28 National Research Council Of Canada Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
EP2267450B1 (en) 2005-04-29 2015-01-28 The Regents of The University of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
AU2006279945B2 (en) 2005-08-10 2012-04-12 Macrogenics, Inc. Identification and engineering of antibodies with variant FC regions and methods of using same
US8007794B2 (en) 2005-11-14 2011-08-30 Rinat Neuroscience Corporation Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
EP3006466B1 (en) 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
KR101538521B1 (ko) 2005-12-15 2015-07-22 제넨테크, 인크. 폴리유비퀴틴 표적화를 위한 방법 및 조성물
ES2807928T3 (es) 2005-12-29 2021-02-24 Janssen Biotech Inc Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
CA2638785C (en) 2006-01-05 2017-02-21 Genentech, Inc. Anti-ephb4 antibodies and methods using same
EP1982181B1 (en) 2006-02-06 2010-12-15 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RS54156B1 (sr) 2006-03-21 2015-12-31 Genentech Inc. Kombinovana terapija koja uključuje alfa5beta1 antagoniste
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2007227195A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
SG10201501103RA (en) 2006-05-30 2015-04-29 Genentech Inc Antibodies And Immunoconjugates And Uses Therefor
WO2008036135A2 (en) 2006-06-01 2008-03-27 Genentech, Inc. Crystal structure of crig and c3b: crig complex
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7981866B2 (en) 2006-07-11 2011-07-19 University Of Medicine And Dentistry Of New Jersey MG53 compositions and methods of use
MX2009000696A (es) 2006-07-19 2009-01-30 Univ Pennsylvania Wsx-1/p28 como un objetivo para respuestas anti-inflamatorias.
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp ORGANIC PROTEINS AND METHOD OF USE THEREOF
WO2008022390A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Anti-c5ar antibodies with improved properties
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008060776A2 (en) 2006-10-03 2008-05-22 University Of Medicine And Dentistry Of New Jersey Atap peptides, nucleic acids encoding the same and associated methods of use
DK2061814T3 (da) 2006-10-27 2012-08-27 Genentech Inc Antistoffer og immunokonjugater og anvendelse deraf.
WO2008140587A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Rhamm, a co-receptor and its interactions with other receptors in cancer cell motility and the identification of cancer prognitor cell populations
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
EP2140021B1 (en) 2007-02-22 2012-01-11 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PT2173381E (pt) 2007-05-14 2013-12-13 Novimmune Sa Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
AU2008258277B2 (en) 2007-06-08 2012-07-12 Australian Poultry Crc Pty Ltd Clostridial toxin NetB
CN112480255B (zh) 2007-07-09 2024-09-27 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
ES2502217T3 (es) 2007-10-02 2014-10-03 Genentech, Inc. Antagonistas de NLRR-1 y sus usos
DK2514436T3 (en) 2007-11-07 2018-03-12 Genentech Inc IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
MX2010005893A (es) 2007-11-29 2011-03-04 Genentech Inc Star Marcadores de expresion genica para enfermedad inflamatoria de intestino.
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ586611A (en) 2007-12-06 2012-09-28 Dana Farber Cancer Inst Inc Antibodies against influenza virus and methods of use thereof
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
JP5568478B2 (ja) 2007-12-18 2014-08-06 バイオアライアンス セー．フェー． 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AR070168A1 (es) 2008-01-31 2010-03-17 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
SI2279412T1 (sl) 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
US20100255508A1 (en) 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
US20100129375A1 (en) 2008-09-10 2010-05-27 Genentech, Inc. Methods for inhibiting ocular angiogenesis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
AR073829A1 (es) 2008-10-14 2010-12-01 Genentech Inc Variantes de inmunoglobulinas y sus usos.
ES2719496T3 (es) 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
CA2747248A1 (en) 2008-12-17 2010-07-15 Sharookh Kapadia Hepatitis c virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI0918204A2 (pt) 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2679600A1 (en) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2766737A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
AU2010276392A1 (en) 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
KR20190018041A (ko) 2009-08-06 2019-02-20 제넨테크, 인크. 단백질 정제 시의 바이러스 제거의 개선방법
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
ES2793348T5 (en) 2009-08-11 2025-04-11 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
SG10201406420XA (en) 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
CA2778481A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
ES2636971T3 (es) 2009-11-05 2017-10-10 F. Hoffmann-La Roche Ag Procedimientos y composición para la secreción de polipéptidos heterógenos
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
AR079556A1 (es) 2009-12-21 2012-02-01 Genentech Inc Formacion de anticuerpos
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
US20130137584A1 (en) 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
CA2790488C (en) 2010-02-18 2018-09-25 The Regents Of The University Of California Integrin .alpha.v.beta.8 neutrilizing antibody
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
JP5887337B2 (ja) 2010-03-30 2016-03-16 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
JP5934190B2 (ja) 2010-05-25 2016-06-15 ジェネンテック， インコーポレイテッド ポリペプチドの精製方法
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
CA2800531C (en) 2010-06-02 2021-05-25 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
KR101834026B1 (ko) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
SG187965A1 (en) 2010-08-27 2013-04-30 Stem Centrx Inc Notum protein modulators and methods of use
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
CN106279415A (zh) 2010-12-08 2017-01-04 施特姆森特克斯股份有限公司 新型调节子及使用方法
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20130137688A (ko) 2011-03-31 2013-12-17 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
DK2773438T4 (da) 2011-11-02 2022-01-03 Hoffmann La Roche Overladnings- og elueringskromatografi
RS62689B1 (sr) 2011-11-04 2021-12-31 Zymeworks Inc Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
SG10201700160RA (en) 2012-02-06 2017-03-30 Inhibrx Lp Cd47 antibodies and methods of use thereof
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
JP6419064B2 (ja) 2012-03-29 2018-11-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP2847230B1 (en) 2012-05-10 2020-08-12 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
BR112014031028A2 (pt) 2012-06-11 2017-08-15 Amgen Inc Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
WO2014018554A1 (en) 2012-07-23 2014-01-30 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
IN2015MN00139A (enExample) 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
CN114507282B (zh) 2012-10-04 2025-05-16 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
EP2917237A1 (en) 2012-11-09 2015-09-16 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CA3155275A1 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
TWI670081B (zh) 2013-02-22 2019-09-01 美商艾伯維史坦森特瑞斯有限責任公司 新穎抗體結合物及其用途
IL269947B (en) 2013-03-13 2022-08-01 Genentech Inc Formulations with reduced oxidation
SG11201507475UA (en) 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
RS60534B1 (sr) 2013-03-13 2020-08-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
JP6427552B2 (ja) 2013-03-15 2018-11-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド フラビウイルス中和抗体およびその使用方法
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
KR20210037745A (ko) 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
KR102207859B1 (ko) 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
WO2014160753A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
KR20160005749A (ko) 2013-05-07 2016-01-15 리나트 뉴로사이언스 코프. 항-글루카곤 수용체 항체 및 이의 사용 방법
EP3536699A1 (en) 2013-07-12 2019-09-11 F. Hoffmann-La Roche AG Elucidation of ion exchange chromatography input optimization
JP6636920B2 (ja) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
RU2016111139A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
KR20210123433A (ko) 2013-08-29 2021-10-13 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
LT3049441T (lt) 2013-09-27 2020-02-10 F. Hoffmann-La Roche Ag Anti-pdl1 antikūnų kompozicija
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
MX388027B (es) 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
JP6667437B2 (ja) 2013-12-02 2020-03-18 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
SG10202002334PA (en) 2013-12-17 2020-05-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
KR102534681B1 (ko) 2013-12-24 2023-05-18 잔센파마슈티카엔.브이. 항-vista 항체 및 단편
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
BR112016021423A2 (pt) 2014-03-21 2017-11-14 Teva Pharmaceuticals Int Gmbh anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
EP3131917B1 (en) 2014-04-18 2020-06-17 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
ES2761675T3 (es) 2014-05-30 2020-05-20 Henlix Biotech Co Ltd Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
ME03678B (me) 2014-06-17 2020-10-20 Univ California Unapređena alfa-v beta-8 antitela
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CA2962976A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
AU2015342964B2 (en) 2014-11-05 2021-06-24 Genentech, Inc. Methods of producing two chain proteins in bacteria
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
ES2789351T3 (es) 2015-01-13 2020-10-26 Hope City Máscaras de enlace peptídico de proteínas de unión a CTLA4
CA2972986A1 (en) 2015-01-16 2016-07-21 City Of Hope Cell penetrating antibodies
CA2972731A1 (en) 2015-01-24 2016-07-28 Chi-Huey Wong Cancer markers and methods of use thereof
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
CN113209289A (zh) 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
WO2016161018A1 (en) 2015-03-30 2016-10-06 City Of Hope Mechanically interlocking complexes
JP6903587B2 (ja) 2015-04-03 2021-07-14 ユーリカ セラピューティックス， インコーポレイテッド Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
MX2017013297A (es) 2015-04-13 2018-06-19 Pfizer Anticuerpos terapeuticos y sus usos.
KR20170138556A (ko) 2015-05-01 2017-12-15 다나-파버 캔서 인스티튜트 인크. 항ccr4 항체를 이용하여 사이토카인 발현을 매개하는 방법
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
WO2016187158A1 (en) 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
MX388166B (es) 2015-06-17 2025-03-19 Genentech Inc Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP3331543A4 (en) 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use
EP3344657A1 (en) 2015-09-02 2018-07-11 The Regents of the University of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
PT3359572T (pt) 2015-10-06 2025-01-27 H Hoffnabb La Roche Ag Método para o tratamento da esclerose múltipla
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
TW201733621A (zh) 2015-12-10 2017-10-01 世代好公司 細胞穿透性之花青耦合抗體
MX391382B (es) 2015-12-24 2025-03-21 Corvus Pharmaceuticals Inc Métodos de tratamiento de cáncer
SG10202103844WA (en) 2015-12-30 2021-06-29 Genentech Inc Use of tryptophan derivatives for protein formulations
KR102796135B1 (ko) 2015-12-30 2025-04-16 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
TWI657096B (zh) 2016-01-21 2019-04-21 輝瑞股份有限公司 對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017173302A2 (en) 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN114703244A (zh) 2016-05-10 2022-07-05 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
CA3026518A1 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
AU2017300788B2 (en) 2016-07-22 2023-11-16 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
CN109716127B (zh) 2016-08-15 2022-06-14 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018048939A1 (en) 2016-09-06 2018-03-15 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
CN109923126B (zh) 2016-09-16 2022-06-03 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
EP3515494A4 (en) 2016-09-26 2020-10-07 The Brigham and Women's Hospital, Inc. REGULATORS OF B-LYMPHOCYTES MEDIA IMMUNOSUPPRESSION
CA3036232C (en) 2016-09-29 2025-11-18 The Regents Of The University Of California Neutralizing antibodies directed against the Integrin Alpha V Beta 8 complex for immunotherapy
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
EP3535299A1 (en) 2016-11-04 2019-09-11 Novimmune S.A. Anti-cd19 antibodies and methods of use thereof
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
IL323048A (en) 2016-11-16 2025-10-01 Janssen Biotech Inc Method for treating psoriasis with a specific anti-IL-23 antibody
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
CN110709419B (zh) 2017-01-06 2023-11-28 博奥信生物技术（南京）有限公司 Erbb2抗体及其用途
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
RU2019127550A (ru) 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
US20230192839A1 (en) 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019090329A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
EP3765005A4 (en) 2018-03-13 2022-02-23 The Regents of the University of California Inhibitors of integrin alpha 2 beta 1 and methods of use
US11203646B2 (en) 2018-03-14 2021-12-21 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
MA52968A (fr) 2018-06-23 2021-04-28 Hoffmann La Roche Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3104147A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
AR115925A1 (es) 2018-08-08 2021-03-10 Genentech Inc Uso de derivados de triptófano y l-metionina para formulación de proteínas
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
US20210393740A1 (en) 2018-09-19 2021-12-23 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
EP4249917A3 (en) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
TWI872030B (zh) 2018-11-05 2025-02-11 美商建南德克公司 在原核宿主細胞中產生二鏈蛋白質之方法
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
SG11202111345PA (en) 2019-04-19 2021-11-29 Chugai Pharmaceutical Co Ltd Chimeric receptor that recognizes engineered site in antibody
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
MA56124A (fr) 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
JPWO2021010326A1 (enExample) 2019-07-12 2021-01-21
CA3145278A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
AU2021220847A1 (en) 2020-02-11 2022-09-01 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
CN115515634A (zh) 2020-05-05 2022-12-23 詹森生物科技公司 用抗il23特异性抗体治疗克罗恩病的方法
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
CA3189402A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
JP2024503724A (ja) 2021-01-20 2024-01-26 オンコレスポンス，インク． 免疫調節抗体およびその使用
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
JP2024510744A (ja) 2021-03-12 2024-03-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
EP4313309A1 (en) 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2022383057A1 (en) 2021-11-05 2024-05-16 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
AU2022388887A1 (en) 2021-11-15 2024-07-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc Method of treating ulcerative colitis with anti-il23 specific antibody
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
CA3254549A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE
AU2023247337A1 (en) 2022-03-30 2024-11-14 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
CN119421701A (zh) 2022-04-01 2025-02-11 基因泰克公司 用以使多肽稳定的羟丙基甲基纤维素衍生物
US20250289903A1 (en) 2022-04-29 2025-09-18 Purinnomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
IL317070A (en) 2022-05-18 2025-01-01 Janssen Biotech Inc Method for evaluating and treating psoriatic arthritis with IL23 antibody
IL320152A (en) 2022-10-21 2025-06-01 Novimmune Sa Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
JP2025539830A (ja) 2022-11-22 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
EP4665392A2 (en) 2023-02-14 2025-12-24 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
CN117190671B (zh) * 2023-09-13 2025-08-26 莱阳银通纸业有限公司 一种种子纸快速风干设备及方法
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025114357A1 (en) 2023-11-28 2025-06-05 Novimmune Sa Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
WO2025196691A1 (en) 2024-03-20 2025-09-25 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8030023B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. Nucleic acid encoding DR5 antibodies and uses thereof
US8409570B2 (en) 2005-02-02 2013-04-02 Genentech, Inc. Method of inducing apoptosis using anti-DR5 antibodies
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9217048B2 (en) 2010-05-17 2015-12-22 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US9731288B2 (en) 2010-05-17 2017-08-15 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US11091551B2 (en) 2012-10-05 2021-08-17 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Also Published As

Publication number Publication date
FR2413974B1 (enExample) 1982-12-03
DE2860970D1 (en) 1981-11-12
FR2413974A1 (fr) 1979-08-03
EP0003089A1 (fr) 1979-07-25

Similar Documents

Publication Publication Date Title
EP0003089B1 (fr) Séchoir pour feuilles imprimées par sérigraphie
EP0039526B1 (fr) Dispositif de transport pour le transfert des feuilles fraîchement imprimées
CH402388A (fr) Appareil pour le façonnage d'articles à partir d'une feuille thermoplastique
EP0015314A1 (fr) Dispositif d'alimentation du papier sur une platine cylindrique tournante d'imprimante
BE1004555A3 (fr) Machine pour decouenner du lard.
EP0229554A1 (fr) Appareil pour la fixation d'agrafes de jonction sur un tapis transporteur ou similaire
EP0780065A1 (fr) Dispositif d'assemblage de la tige et de la semelle d'une chaussure
EP0424290B1 (fr) Dispositif de positionnement d'un produit en forme de feuille souple
FR2541562A1 (fr) Procede de greffage automatique de la vigne et machine comportant application de ce procede
EP0086867B1 (fr) Machine à étiqueter portative
EP0220967B1 (fr) Convoyeur de récipients
EP0578551B1 (fr) Perfectionnements aux machines d'impression, notamment aux machines de sérigraphie
EP0391772A1 (fr) Appareil pour la fixation d'agrafes de jonction sur un tapis transporteur ou similaire
EP0252844B1 (fr) Machine automatique pour le traitement d'un matériau en bande et notamment pour la découpe d'un tel matériau
FR2575629A1 (fr) Dispositif de montage automatique sur un substrat d'elements de circuit du type puce
FR2733491A1 (fr) Dispositif de sortie d'exemplaires imprimes d'un dispositif a roues a aubes
EP0320342B1 (fr) Plieuse
EP0259235A1 (fr) Machine pour le prélèvement automatique de peaux ou similaires à partir d'une pile
EP0219444B1 (fr) Machine de fendage de bois à cône fileté rotatif
FR2649086A1 (fr) Distributeur de supports souples
FR2766411A1 (fr) Mecanisme d'impression thermique
CH632712A5 (en) Labelling device, particularly for bottles
FR2477504A1 (fr) Dispositif pour le pliage et le collage de bandes adhesives sur des documents plats
EP0303654B1 (fr) Procede pour former le fond d'un sachet en matiere synthetique souple et dispositif pour sa mise en oeuvre
EP0249568A1 (fr) Manipulateur de bobines de fil pour centrifugeuses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

17P Request for examination filed
ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

REF Corresponds to:

Ref document number: 2860970

Country of ref document: DE

Date of ref document: 19811112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19811231

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: SVECIA SILKSCREEN MASKINER AB

Effective date: 19820218

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: LINDBLOM, ERIK J.

Effective date: 19820218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19831031

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19831130

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19831231

Year of fee payment: 6

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841221

Year of fee payment: 7

Ref country code: CH

Payment date: 19841221

Year of fee payment: 7

27O Opposition rejected

Effective date: 19840722

NLR2 Nl: decision of opposition
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19851231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19861231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19870701

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19871228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19871231

BERE Be: lapsed

Owner name: SILIUM S.F.A.R.L.

Effective date: 19871231

Owner name: DAVID BERNARD

Effective date: 19871231

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78400265.1

Effective date: 19880912